GV had led an oversubscribed series D round for the gene therapy developer that also featured Illumina Ventures and SoftBank Vision Fund II.

GV, a corporate venture capital subsidiary of internet and technology conglomerate Alphabet, led a $135m series D round for US-based precision gene therapy developer Encoded Therapeutics yesterday.

The oversubscribed round also featured Illumina Ventures and SoftBank Vision Fund II, which invested on behalf of biotechnology producer Illumina and telecommunications and internet group SoftBank respectively.

Matrix Capital Management, Arch Venture Partners, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management and undisclosed additional investors filled…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn